Abstract
Diffuse large B-cell lymphoma (DLBCL) is a hematological cancer associated with an aggressive clinical course. The predominant subtypes of DLBCL display features of chronic or tonic B-cell antigen receptor (BCR) signaling. However, it is not known whether the spatial organization of the BCR contributes to the regulation of pro-survival signaling pathways and cell growth. Here, we show that primary DLBCL tumors and patient-derived DLBCL cell lines contain high levels of phosphorylated Ezrin-Radixin-Moesin (ERM) proteins. The surface BCRs in both activated B cell and germinal B cell subtype DLBCL cells co-segregate with phosphoERM suggesting that the cytoskeletal network may support localized BCR signaling and contribute to pathogenesis. Indeed, ablation of membrane-cytoskeletal linkages by dominant-negative mutants, pharmacological inhibition and knockdown of ERM proteins disrupted cell surface BCR organization, inhibited proximal and distal BCR signaling, and reduced the growth of DLBCL cell lines. In vivo administration of the ezrin inhibitor retarded the growth of DLBCL tumor xenografts, concomitant with reduction in intratumor phosphoERM levels, dampened pro-survival signaling and induction of apoptosis. Our results reveal a novel ERM-based spatial mechanism that is coopted by DLBCL cells to sustain tumor cell growth and survival.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Coiffier B . Current strategies for the treatment of diffuse large B cell lymphoma. Curr Opin Hematol 2005; 12: 259–265.
Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM . A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003; 100: 9991–9996.
Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA 2008; 105: 13520–13525.
Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198: 851–862.
Schneider C, Pasqualucci L, Dalla-Favera R . Molecular pathogenesis of diffuse large B-cell lymphoma. Semin Diagn Pathol 2011; 28: 167–177.
Shaffer AL 3rd, Young RM, Staudt LM . Pathogenesis of human B cell lymphomas. Annu Rev Immunol 2012; 30: 565–610.
Sehn LH, Connors JM . Treatment of aggressive non-Hodgkin's lymphoma: a north American perspective. Oncology (Williston Park) 2005; 19: 26–34.
Sehn LH, Connors JM . Treatment of diffuse large B-cell lymphoma: a risk-based approach. Clin Lymphoma Myeloma 2006; 7: S14–S19.
Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010; 463: 88–92.
Young RM, Staudt LM . Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov 2013; 12: 229–243.
Ansell SM, Hodge LS, Secreto FJ, Manske M, Braggio E, Price-Troska T et al. Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma. Blood Cancer J 2014; 4: e183.
Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008; 319: 1676–1679.
Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009; 459: 717–721.
Ibrutinib approved for mantle cell lymphoma. Cancer Discov 2014; 4: OF1.
Cheng S, Ma J, Guo A, Lu P, Leonard JP, Coleman M et al. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia 2013; 28: 649–657.
Fehon RG, McClatchey AI, Bretscher A . Organizing the cell cortex: the role of ERM proteins. Nat Rev Mol Cell Biol 2010; 11: 276–287.
Yonemura S, Matsui T, Tsukita S . Rho-dependent and -independent activation mechanisms of ezrin/radixin/moesin proteins: an essential role for polyphosphoinositides in vivo. J Cell Sci 2002; 115: 2569–2580.
Fievet BT, Gautreau A, Roy C, Del Maestro L, Mangeat P, Louvard D et al. Phosphoinositide binding and phosphorylation act sequentially in the activation mechanism of ezrin. J Cell Biol 2004; 164: 653–659.
Bretscher A, Chambers D, Nguyen R, Reczek D . ERM-Merlin and EBP50 protein families in plasma membrane organization and function. Annu Rev Cell Dev Biol 2000; 16: 113–143.
Yonemura S, Tsukita S, Tsukita S . Direct involvement of ezrin/radixin/moesin (ERM)-binding membrane proteins in the organization of microvilli in collaboration with activated ERM proteins. J Cell Biol 1999; 145: 1497–1509.
Viswanatha R, Bretscher A, Garbett D . Dynamics of ezrin and EBP50 in regulating microvilli on the apical aspect of epithelial cells. Biochem Soc Trans 2014; 42: 189–194.
Treanor B, Depoil D, Gonzalez-Granja A, Barral P, Weber M, Dushek O et al. The membrane skeleton controls diffusion dynamics and signaling through the B cell receptor. Immunity 2010; 32: 187–199.
Gupta N, Wollscheid B, Watts JD, Scheer B, Aebersold R, DeFranco AL . Quantitative proteomic analysis of B cell lipid rafts reveals that ezrin regulates antigen receptor-mediated lipid raft dynamics. Nat Immunol 2006; 7: 625–633.
Viola A, Gupta N . Tether and trap: regulation of membrane-raft dynamics by actin-binding proteins. Nat Rev Immunol 2007; 7: 889–896.
Batista FD, Treanor B, Harwood NE . Visualizing a role for the actin cytoskeleton in the regulation of B-cell activation. Immunol Rev 2010; 237: 191–204.
Liu W, Meckel T, Tolar P, Sohn HW, Pierce SK . Intrinsic properties of immunoglobulin IgG1 isotype-switched B cell receptors promote microclustering and the initiation of signaling. Immunity 2010; 32: 778–789.
Liu W, Meckel T, Tolar P, Sohn HW, Pierce SK . Antigen affinity discrimination is an intrinsic function of the B cell receptor. J Exp Med 2010; 207: 1095–1111.
Klasener K, Maity PC, Hobeika E, Yang J, Reth M . B cell activation involves nanoscale receptor reorganizations and inside-out signaling by Syk. eLife 2014; 3: e02069.
Treanor B, Depoil D, Bruckbauer A, Batista FD . Dynamic cortical actin remodeling by ERM proteins controls BCR microcluster organization and integrity. J Exp Med 2011; 208: 1055–1068.
Pore D, Parameswaran N, Matsui K, Stone MB, Saotome I, McClatchey AI et al. Ezrin tunes the magnitude of humoral immunity. J Immunol 2013; 191: 4048–4058.
Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275–282.
Parameswaran N, Matsui K, Gupta N . Conformational switching in ezrin regulates morphological and cytoskeletal changes required for B cell chemotaxis. J Immunol 2011; 186: 4088–4097.
Crepaldi T, Gautreau A, Comoglio PM, Louvard D, Arpin M . Ezrin is an effector of hepatocyte growth factor-mediated migration and morphogenesis in epithelial cells. J Cell Biol 1997; 138: 423–434.
Parameswaran N, Enyindah-Asonye G, Bagheri N, Shah NB, Gupta N . Spatial coupling of JNK activation to the B cell antigen receptor by tyrosine-phosphorylated ezrin. J Immunol 2013; 190: 2017–2026.
Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 2004; 10: 182–186.
Li Q, Wu M, Wang H, Xu G, Zhu T, Zhang Y et al. Ezrin silencing by small hairpin RNA reverses metastatic behaviors of human breast cancer cells. Cancer Lett 2008; 261: 55–63.
Monni R, Haddaoui L, Naba A, Gallais I, Arpin M, Mayeux P et al. Ezrin is a target for oncogenic Kit mutants in murine erythroleukemia. Blood 2008; 111: 3163–3172.
Bulut G, Hong SH, Chen K, Beauchamp EM, Rahim S, Kosturko GW et al. Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells. Oncogene 2012; 31: 269–281.
Lam LT, Davis RE, Pierce J, Hepperle M, Xu Y, Hottelet M et al. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 2005; 11: 28–40.
Kloo B, Nagel D, Pfeifer M, Grau M, Duwel M, Vincendeau M et al. Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci USA 2011; 108: 272–277.
Pierce SK, Liu W . The tipping points in the initiation of B cell signalling: how small changes make big differences. Nat Rev Immunol 2010; 10: 767–777.
Tolar P, Hanna J, Krueger PD, Pierce SK . The constant region of the membrane immunoglobulin mediates B cell-receptor clustering and signaling in response to membrane antigens. Immunity 2009; 30: 44–55.
Tolar P, Meckel T . Imaging B-cell receptor signaling by single-molecule techniques. Methods Mol Biol 2009; 571: 437–453.
Yu D, Cook MC, Shin DM, Silva DG, Marshall J, Toellner KM et al. Axon growth and guidance genes identify T-dependent germinal centre B cells. Immunol Cell Biol 2008; 86: 3–14.
Bretscher A, Edwards K, Fehon RG . ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol 2002; 3: 586–599.
Fornasiero EF, Opazo F . Super-resolution imaging for cell biologists: Concepts, applications, current challenges and developments. Bioessays 2015; 37: 436–451.
Lillemeier BF, Mortelmaier MA, Forstner MB, Huppa JB, Groves JT, Davis MM . TCR and Lat are expressed on separate protein islands on T cell membranes and concatenate during activation. Nat Immunol 2010; 11: 90–96.
Shelby SA, Holowka D, Baird B, Veatch SL . Distinct stages of stimulated FcepsilonRI receptor clustering and immobilization are identified through superresolution imaging. Biophys J 2013; 105: 2343–2354.
Mattila PK, Feest C, Depoil D, Treanor B, Montaner B, Otipoby KL et al. The actin and tetraspanin networks organize receptor nanoclusters to regulate B cell receptor-mediated signaling. Immunity 2013; 38: 461–474.
Blonska M, Lin X . CARMA1-mediated NF-kappaB and JNK activation in lymphocytes. Immunol Rev 2009; 228: 199–211.
Rickert RC . New insights into pre-BCR and BCR signalling with relevance to B cell malignancies. Nat Rev Immunol 2013; 13: 578–591.
Baracho GV, Miletic AV, Omori SA, Cato MH, Rickert RC . Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation. Curr Opin Immunol 2011; 23: 178–183.
Delgado P, Cubelos B, Calleja E, Martinez-Martin N, Cipres A, Merida I et al. Essential function for the GTPase TC21 in homeostatic antigen receptor signaling. Nat Immunol 2009; 10: 880–888.
Clark MR, Campbell KS, Kazlauskas A, Johnson SA, Hertz M, Potter TA et al. The B cell antigen receptor complex: association of Ig-alpha and Ig-beta with distinct cytoplasmic effectors. Science 1992; 258: 123–126.
Cherukuri A, Cheng PC, Sohn HW, Pierce SK . The CD19/CD21 complex functions to prolong B cell antigen receptor signaling from lipid rafts. Immunity 2001; 14: 169–179.
Depoil D, Fleire S, Treanor BL, Weber M, Harwood NE, Marchbank KL et al. CD19 is essential for B cell activation by promoting B cell receptor-antigen microcluster formation in response to membrane-bound ligand. Nat Immunol 2008; 9: 63–72.
Zotos D, Tarlinton DM . Determining germinal centre B cell fate. Trends Immunol 2012; 33: 281–288.
Allen CD, Okada T, Tang HL, Cyster JG . Imaging of germinal center selection events during affinity maturation. Science 2007; 315: 528–531.
Ohnishi K, Melchers F . The nonimmunoglobulin portion of lambda5 mediates cell-autonomous pre-B cell receptor signaling. Nat Immunol 2003; 4: 849–856.
Chen Y, Wang D, Guo Z, Zhao J, Wu B, Deng H et al. Rho kinase phosphorylation promotes ezrin-mediated metastasis in hepatocellular carcinoma. Cancer Res 2011; 71: 1721–1729.
Elliott BE, Meens JA, SenGupta SK, Louvard D, Arpin M . The membrane cytoskeletal crosslinker ezrin is required for metastasis of breast carcinoma cells. Breast Cancer Res 2005; 7: R365–R373.
Legg JW, Lewis CA, Parsons M, Ng T, Isacke CM . A novel PKC-regulated mechanism controls C4D44 ezrin association and directional cell motility. Nat Cell Biol 2002; 4: 399–407.
Chen L, Monti S, Juszczynski P, Daley J, Chen W, Witzig TE et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 2008; 111: 2230–2237.
Idelalisib approved for trio of blood cancers. Cancer Discov 2014; 4: OF6.
Naylor TL, Tang H, Ratsch BA, Enns A, Loo A, Chen L et al. Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas. Cancer Res 2011; 71: 2643–2653.
Acknowledgements
This study was funded by grants to NG (AI081743 from NIH and Cancer Research Institute Investigator Award). We thank Yvonne Parker for assistance with the animal experiments.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Pore, D., Bodo, J., Danda, A. et al. Identification of Ezrin-Radixin-Moesin proteins as novel regulators of pathogenic B-cell receptor signaling and tumor growth in diffuse large B-cell lymphoma. Leukemia 29, 1857–1867 (2015). https://doi.org/10.1038/leu.2015.86
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2015.86
This article is cited by
-
NSC305787, a pharmacological ezrin inhibitor, exhibits antineoplastic activity in pancreatic cancer cells
Investigational New Drugs (2022)
-
Moesin as a prognostic indicator of lung adenocarcinoma improves prognosis by enhancing immune lymphocyte infiltration
World Journal of Surgical Oncology (2021)
-
Comprehensive analysis of cytoskeleton regulatory genes identifies ezrin as a prognostic marker and molecular target in acute myeloid leukemia
Cellular Oncology (2021)
-
MARCKS regulates tonic and chronic active B cell receptor signaling
Leukemia (2019)
-
Kallikrein-related peptidases 4, 5, 6 and 7 regulate tumour-associated factors in serous ovarian cancer
British Journal of Cancer (2018)